NCT04526106
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04526106
Title REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Elevar Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | AUS

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field